| Literature DB >> 35507665 |
Felipe B d'Andrea1,2, Nicholas C Poulton1, Ruby Froom1,3, Kayan Tam1, Elizabeth A Campbell3, Jeremy M Rock1.
Abstract
The Clp protease system is a promising, noncanonical drug target against Mycobacterium tuberculosis (Mtb). Unlike in Escherichia coli, the Mtb Clp protease consists of two distinct proteolytic subunits, ClpP1 and ClpP2, which hydrolyze substrates delivered by the chaperones ClpX and ClpC1. While biochemical approaches uncovered unique aspects of Mtb Clp enzymology, its essentiality complicates in vivo studies. To address this gap, we leveraged new genetic tools to mechanistically interrogate the in vivo essentiality of the Mtb Clp protease. While validating some aspects of the biochemical model, we unexpectedly found that only the proteolytic activity of ClpP1, but not of ClpP2, is essential for substrate degradation and Mtb growth and infection. Our observations not only support a revised model of Mtb Clp biology, where ClpP2 scaffolds chaperone binding while ClpP1 provides the essential proteolytic activity of the complex; they also have important implications for the ongoing development of inhibitors toward this emerging therapeutic target.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35507665 PMCID: PMC9067928 DOI: 10.1126/sciadv.abn7943
Source DB: PubMed Journal: Sci Adv ISSN: 2375-2548 Impact factor: 14.957
Fig. 1.The Mtb Clp protease is functionally asymmetric in vivo.
(A) Growth of the indicated Mtb CRISPRi strains. ATc induces expression of dCas9 and the single-guide RNA (sgRNA). NT, nontargeting sgRNA; EV, empty complementation vector; KD, knockdown; S98, Mtb ClpP1 catalytic serine; CR, CRISPRi-resistant allele; S110, Mtb ClpP2 catalytic serine; hp, hydrophobic patch mutations: P1, S61A, Y63V, L83A, and Y91V; P2, Y75V and Y95V. (B) Growth of the indicated Msmeg CRISPRi strains. S95, Msmeg ClpP1 catalytic serine; S114, Msmeg ClpP2 catalytic serine; ΔM1-A16, Msmeg clpP2 allele expressed without the propeptide; WT, wild type.
Fig. 2.ClpP1, but not ClpP2, proteolytic activity is necessary and sufficient for the turnover of mScarlet-YALAA and WhiB1.
(A and B) Time-lapse microscopy (A) and immunoblot (B) measuring mScarlet-YALAA accumulation in the indicated Msmeg CRISPRi strains. t (h), hours after ATc addition. (C) Immunoblot of Msmeg 3xFLAG-WhiB1 and C-terminally truncated Msmeg 3xFLAG-WhiB1ΔK72-V84 from log-phase bacterial cultures. (D) Growth of the indicated Msmeg CRISPRi strains. ΔK72-V84, WhiB1 C-terminal truncation. (E) Immunoblot measuring 3xFLAG-WhiB1 levels in the indicated Msmeg CRISPRi strains. TRITC, tetramethyl rhodamine isothiocyanate.
Fig. 3.Mtb ClpP2 proteolytic activity is nonessential during mouse infection or antibiotic treatment.
(A) Growth of the indicated recombineered Mtb strains. Data represent the mean of eight technical triplicates ± SD. OD600, optical density at 600 nm. (B) Colony-forming units (CFU) in lungs and spleens of C57BL/6J mice low-dose aerosol–infected with Mtb strains shown in (A). Data are mean CFUs per organ ± SD of five mice. (C) Minimum inhibitory concentration curves of recombineered Mtb strains with the indicated antibiotics. Data represent the mean of technical triplicates ± SD.